Relmada Therapeutics, Inc.
RLMDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRelmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company carries a $348.8M market cap, placing it firmly in the small-cap category. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
Market Cap
$348.8M
Beta
0.51
P/E (TTM)
—
P/E (Fwd)
-7.98
EPS (TTM)
$-0.91
EPS (Fwd)
$-0.41
ROE
-55.7%
ROA
-32.4%
Cash
$217.7M
Total Debt
$0
Free CF
-$23.7M
52W Change
40.3%
Annual Financials
Cash vs Debt
Where RLMD stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, RLMD finished 46.18% below its 150-day moving average ($5.76) and 42.59% below its 200-day moving average ($5.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RLMD overbought or oversold?
At the October 19, 2026 close, RLMD's RSI(14) was 26.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Relmada Therapeutics, Inc. reports $217.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$23.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -55.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
RLMD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RLMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.